Atai Beckley Inc.
- ATAI
- NASDAQ
- Biotechnology
- Mental Health Drug Development
- Clinical-Stage Biopharma
$7.35
Quote Sep 11, 2026, 01:30 PM UTC
+1.66%over the last month
Max drawdown −2.2%From 1-month high −1.2%3 months +93.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Atai Beckley
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
99
Market value
$2.73B
Quote Sep 11
Floor
$7.35
0.0% below price
Resistance
$7.41
0.8% above price
Price vs analyst targets
8 analysts
Lowest target
$7.45Highest target
$8.00
$7.45Highest target
$8.00
- Price $7.35
- Average target $7.69
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 5% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ATAIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free